Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.48 |
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | ABL1 | P00519 | 6/20 | 0.48 |
| ▸ | ABL2 | P42684 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.47 |
| ▸ | KIF5B | P33176 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 5/20 | 0.47 |
| ▸ | LCK | P06239 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.44 |
| ▸ | NEK7 | Q8TDX7 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867277 | 0.92 | EIF2AK3 (0.47) | SRCKDRRETKIF5BKCNH2 | |
| SCHEMBL7006035 | 0.91 | SRC (0.49) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL2074527 | 0.89 | ABL1 (0.50) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL6871561 | 0.88 | RET (0.44) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL2074179 | 0.83 | SRC (0.59) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL6867323 | 0.81 | ABL1 (0.48) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL16930842 | 0.81 | TEK (0.56) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL7005371 | 0.80 | TEK (0.61) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL6460212 | 0.79 | TEK (0.74) | SRCEGFRABL1KDRRET | |
| SCHEMBL6867388 | 0.79 | ABL1 (0.45) | SRCEGFRABL1ABL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | SRC 89/4885EGFR 294/4885ABL1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.